septic shock Inotrem nangibotide

Inotrem has reported positive results from a Phase IIa trial of nangibotide (LR12) for the treatment of septic shock patients.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive.

Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday.

Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday.

The pharmaceutical industry's most comprehensive news and information delivered every month.

I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy

SUBSCRIBED

Thank you for subscribing to Clinical Trials Arena

THANK YOU